Ab­b­Vie steers past the wreck­age, re­serves $224M to kick off once-and-done gene ther­a­py with Voy­ager to fight Alzheimer’s

Ab­b­Vie $AB­BV is hitch­ing a ride on the gene ther­a­py tech plat­form at Voy­ager $VY­GR to try a new ap­proach to tack­le Alzheimer’s.

The two com­pa­nies an­nounced this morn­ing that Ab­b­Vie is strik­ing up a col­lab­o­ra­tion to use Voy­ager’s AAV vec­tor tech to de­vel­op new de­liv­ery ve­hi­cles that can de­posit the in­struc­tions need­ed to pro­duce tau-fo­cused an­ti­bod­ies in the brain.

Tau and amy­loid be­ta — pro­teins that can clus­ter in the brain — re­main the two key tar­gets in Alzheimer’s, even af­ter a se­ries of ma­jor set­backs in the field raise fresh ques­tions about how much we know and don’t know about this dev­as­tat­ing dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER